Reporting of Acute Inflammatory Neuropathies with COVID-19 Vaccines: Subgroup Disproportionality Analyses in VigiBase

Since marketing authorization, cases of neuralgic amyotrophy (NA), facial paralysis/Bell’s palsy (FP/BP), and Guillain-Barré syndrome (GBS) were reported with COVID-19 vaccines of different technologies. This study aimed to assess whether NA, FP/BP, and GBS were more frequently reported in VigiBase...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) Vol. 9; no. 9; p. 1022
Main Authors: Noseda, Roberta, Ripellino, Paolo, Ghidossi, Sara, Bertoli, Raffaela, Ceschi, Alessandro
Format: Journal Article
Language:English
Published: Basel MDPI AG 14.09.2021
MDPI
Subjects:
acute inflammatory neuropathy
Age
Bell's palsy
Brief Report
Confidence intervals
Coronaviruses
COVID-19
COVID-19 vaccines
Decision making
disproportionality
Guillain-Barre syndrome
Inflammation
Influenza
Males
Neuropathy
Paralysis
Patients
Risk factors
Risk groups
safety
Sex
Subgroups
Vaccines
VigiBase
United States > US
ISSN:2076-393X, 2076-393X
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Since marketing authorization, cases of neuralgic amyotrophy (NA), facial paralysis/Bell’s palsy (FP/BP), and Guillain-Barré syndrome (GBS) were reported with COVID-19 vaccines of different technologies. This study aimed to assess whether NA, FP/BP, and GBS were more frequently reported in VigiBase with COVID-19 vaccines (of any technologies) than with other viral vaccines, over the full database and across potential risk groups by sex and age. The reporting odds ratio (ROR) with 95% confidence interval (95% CI) was used as the measure of disproportionality and subgroup disproportionality analyses were performed by sex and age. Out of 808,906 safety reports with COVID-19 vaccines, 57 (0.01%) reported NA, 3320 (0.4%) FP/BP, and 632 (0.1%) GBS. There were not signals of disproportionate reporting for NA and GBS with COVID-19 vaccines against other viral vaccines. FP/BP was disproportionately more frequently reported with COVID-19 vaccines than with other viral vaccines over the full database (ROR 1.12, 95%CI 1.07–1.17), in males (ROR 1.65, 95%CI 1.54–1.78) and in age subgroups 65–74 years (ROR 1.21, 95%CI 1.05–1.39) and ≥75 years (ROR 1.84, 95%CI 1.52–2.22). Albeit not proving causation, these findings might support clinicians in decision-making for patients potentially at risk for developing an acute inflammatory neuropathy with COVID-19 vaccines.
AbstractList Since marketing authorization, cases of neuralgic amyotrophy (NA), facial paralysis/Bell's palsy (FP/BP), and Guillain-Barré syndrome (GBS) were reported with COVID-19 vaccines of different technologies. This study aimed to assess whether NA, FP/BP, and GBS were more frequently reported in VigiBase with COVID-19 vaccines (of any technologies) than with other viral vaccines, over the full database and across potential risk groups by sex and age. The reporting odds ratio (ROR) with 95% confidence interval (95% CI) was used as the measure of disproportionality and subgroup disproportionality analyses were performed by sex and age. Out of 808,906 safety reports with COVID-19 vaccines, 57 (0.01%) reported NA, 3320 (0.4%) FP/BP, and 632 (0.1%) GBS. There were not signals of disproportionate reporting for NA and GBS with COVID-19 vaccines against other viral vaccines. FP/BP was disproportionately more frequently reported with COVID-19 vaccines than with other viral vaccines over the full database (ROR 1.12, 95%CI 1.07-1.17), in males (ROR 1.65, 95%CI 1.54-1.78) and in age subgroups 65-74 years (ROR 1.21, 95%CI 1.05-1.39) and ≥75 years (ROR 1.84, 95%CI 1.52-2.22). Albeit not proving causation, these findings might support clinicians in decision-making for patients potentially at risk for developing an acute inflammatory neuropathy with COVID-19 vaccines.Since marketing authorization, cases of neuralgic amyotrophy (NA), facial paralysis/Bell's palsy (FP/BP), and Guillain-Barré syndrome (GBS) were reported with COVID-19 vaccines of different technologies. This study aimed to assess whether NA, FP/BP, and GBS were more frequently reported in VigiBase with COVID-19 vaccines (of any technologies) than with other viral vaccines, over the full database and across potential risk groups by sex and age. The reporting odds ratio (ROR) with 95% confidence interval (95% CI) was used as the measure of disproportionality and subgroup disproportionality analyses were performed by sex and age. Out of 808,906 safety reports with COVID-19 vaccines, 57 (0.01%) reported NA, 3320 (0.4%) FP/BP, and 632 (0.1%) GBS. There were not signals of disproportionate reporting for NA and GBS with COVID-19 vaccines against other viral vaccines. FP/BP was disproportionately more frequently reported with COVID-19 vaccines than with other viral vaccines over the full database (ROR 1.12, 95%CI 1.07-1.17), in males (ROR 1.65, 95%CI 1.54-1.78) and in age subgroups 65-74 years (ROR 1.21, 95%CI 1.05-1.39) and ≥75 years (ROR 1.84, 95%CI 1.52-2.22). Albeit not proving causation, these findings might support clinicians in decision-making for patients potentially at risk for developing an acute inflammatory neuropathy with COVID-19 vaccines.
Since marketing authorization, cases of neuralgic amyotrophy (NA), facial paralysis/Bell’s palsy (FP/BP), and Guillain-Barré syndrome (GBS) were reported with COVID-19 vaccines of different technologies. This study aimed to assess whether NA, FP/BP, and GBS were more frequently reported in VigiBase with COVID-19 vaccines (of any technologies) than with other viral vaccines, over the full database and across potential risk groups by sex and age. The reporting odds ratio (ROR) with 95% confidence interval (95% CI) was used as the measure of disproportionality and subgroup disproportionality analyses were performed by sex and age. Out of 808,906 safety reports with COVID-19 vaccines, 57 (0.01%) reported NA, 3320 (0.4%) FP/BP, and 632 (0.1%) GBS. There were not signals of disproportionate reporting for NA and GBS with COVID-19 vaccines against other viral vaccines. FP/BP was disproportionately more frequently reported with COVID-19 vaccines than with other viral vaccines over the full database (ROR 1.12, 95%CI 1.07–1.17), in males (ROR 1.65, 95%CI 1.54–1.78) and in age subgroups 65–74 years (ROR 1.21, 95%CI 1.05–1.39) and ≥75 years (ROR 1.84, 95%CI 1.52–2.22). Albeit not proving causation, these findings might support clinicians in decision-making for patients potentially at risk for developing an acute inflammatory neuropathy with COVID-19 vaccines.
Author Ceschi, Alessandro
Ripellino, Paolo
Noseda, Roberta
Ghidossi, Sara
Bertoli, Raffaela
AuthorAffiliation 1 Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland; Roberta.noseda@eoc.ch (R.N.); Sara.ghidossi@eoc.ch (S.G.); raffaela.bertoli@eoc.ch (R.B.)
5 Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, 8091 Zurich, Switzerland
3 Clinical Trial Unit, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland
2 Neurology Department, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland; Paolo.ripellino@eoc.ch
4 Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6900 Lugano, Switzerland
AuthorAffiliation_xml – name: 1 Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland; Roberta.noseda@eoc.ch (R.N.); Sara.ghidossi@eoc.ch (S.G.); raffaela.bertoli@eoc.ch (R.B.)
– name: 2 Neurology Department, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland; Paolo.ripellino@eoc.ch
– name: 4 Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6900 Lugano, Switzerland
– name: 3 Clinical Trial Unit, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland
– name: 5 Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, 8091 Zurich, Switzerland
Author_xml – sequence: 1
  givenname: Roberta
  orcidid: 0000-0002-4946-7926
  surname: Noseda
  fullname: Noseda, Roberta
– sequence: 2
  givenname: Paolo
  orcidid: 0000-0002-8662-9656
  surname: Ripellino
  fullname: Ripellino, Paolo
– sequence: 3
  givenname: Sara
  surname: Ghidossi
  fullname: Ghidossi, Sara
– sequence: 4
  givenname: Raffaela
  orcidid: 0000-0002-6602-983X
  surname: Bertoli
  fullname: Bertoli, Raffaela
– sequence: 5
  givenname: Alessandro
  orcidid: 0000-0002-4308-0405
  surname: Ceschi
  fullname: Ceschi, Alessandro
BookMark eNp1kktvGyEUhVGVqkncrLtF6qabSRgew9BFJdfpw1LUSH1Y3SEGmDHWGKYwk8r_vji2qsZS2VwE3zn3CO4lOPPBWwBeleiaEIFuHpTWztskkCgRxs_ABUa8KoggP8_-2Z-Dq5Q2KC9RkrriL8A5oYwLzMQFmL7aIcTR-Q6GFs71NFq49G2vtls1hriDX-wUw6DGtbMJ_nbjGi7uV8vbohRwdez_Fn6bmi6GaYC3Lg0Z3zsGr3o37uA8113KYufhynXuvUr2JXjeqj7Zq2OdgR8fP3xffC7u7j8tF_O7QtOKjgXGgmptKKsaoWxlFMZtjQnhWGDeUINIow0rVcMN5ZY1JoOcGaQ5U4zXhMzA8uBrgtrIIbqtijsZlJOPByF2UuWoureyLLGxlahNy1pqTaMajTCnpai54cTy7PXu4DVMzdYabf0YVf_E9OmNd2vZhQdZU05Ijj0Db44GMfyabBrl1iVt-155G6YkMeOcUl6LOqOvT9BNmGJ-yEeqYoSJap_o5kDpGFKKtv0bpkRyPyHyZEKygp0otBvV_q9yYtf_V_cHa07Ehg
CitedBy_id crossref_primary_10_3390_life12091338
crossref_primary_10_1016_j_nrleng_2022_09_007
crossref_primary_10_1016_j_clinimag_2021_12_008
crossref_primary_10_1007_s40261_022_01164_4
crossref_primary_10_3390_ctn6010007
crossref_primary_10_3390_biomedicines12061248
crossref_primary_10_1016_j_neurol_2023_02_063
crossref_primary_10_1111_ene_16462
crossref_primary_10_1016_j_clinimag_2021_10_010
crossref_primary_10_20986_resed_2025_4120_2023
crossref_primary_10_1136_jnnp_2021_328182
crossref_primary_10_3390_vaccines11020236
Cites_doi 10.1001/jamainternmed.2021.2219
10.1002/mus.25008
10.1016/S1473-3099(21)00076-1
10.1007/s00415-021-10462-4
10.1136/bmj.n1046
10.1002/pmrj.12619
10.1007/s40264-020-00957-w
10.1007/s40264-015-0388-3
10.1002/mus.27255
10.1016/S0140-6736(16)00339-1
10.1136/bcr-2021-243629
10.1002/ana.26144
10.1007/s00415-021-10617-3
10.1093/qjmed/hcab143
10.1016/j.vaccine.2016.05.023
ContentType Journal Article
Copyright 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2021 by the authors. 2021
Copyright_xml – notice: 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2021 by the authors. 2021
DBID AAYXX
CITATION
3V.
7T7
7XB
8FD
8FE
8FH
8FK
8G5
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
C1K
CCPQU
COVID
DWQXO
FR3
GNUQQ
GUQSH
HCIFZ
LK8
M2O
M7P
MBDVC
P64
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.3390/vaccines9091022
DatabaseName CrossRef
ProQuest Central (Corporate)
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Central (purchase pre-March 2016)
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Journals
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
Biological Science Collection
ProQuest Central
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One
Coronavirus Research Database
ProQuest Central
Engineering Research Database
ProQuest Central Student
ProQuest Research Library
SciTech Premium Collection
Biological Sciences
Research Library
Biological Science Database
Research Library (Corporate)
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Research Library
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Central (New)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest One Academic Eastern Edition
Coronavirus Research Database
Biological Science Database
ProQuest SciTech Collection
Biotechnology and BioEngineering Abstracts
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
CrossRef
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: PIMPY
  name: Publicly Available Content Database
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 2076-393X
ExternalDocumentID oai_doaj_org_article_112de698df5f4edbabc02741987d73e7
PMC8473382
10_3390_vaccines9091022
GeographicLocations United States--US
GeographicLocations_xml – name: United States--US
GroupedDBID 53G
5VS
8FE
8FH
8G5
AADQD
AAHBH
AAYXX
ABUWG
ADBBV
AEUYN
AFFHD
AFKRA
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
CCPQU
CITATION
DIK
DWQXO
GNUQQ
GROUPED_DOAJ
GUQSH
HCIFZ
HYE
IAO
IHR
ITC
KQ8
LK8
M2O
M48
M7P
MODMG
M~E
OK1
PGMZT
PHGZM
PHGZT
PIMPY
PQGLB
PQQKQ
PROAC
RNS
RPM
3V.
7T7
7XB
8FD
8FK
C1K
COVID
FR3
MBDVC
P64
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
5PM
ID FETCH-LOGICAL-c464t-2294ccd456b9ae6da22f823372927b4d03bcd51ab7d47e5bd56b75d0c75a57833
IEDL.DBID DOA
ISICitedReferencesCount 15
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000702070000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2076-393X
IngestDate Fri Oct 03 12:51:02 EDT 2025
Tue Nov 04 01:59:13 EST 2025
Sun Nov 09 13:22:45 EST 2025
Fri Jul 25 10:29:23 EDT 2025
Tue Nov 18 22:52:06 EST 2025
Sat Nov 29 07:12:26 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 9
Language English
License Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c464t-2294ccd456b9ae6da22f823372927b4d03bcd51ab7d47e5bd56b75d0c75a57833
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Shared First co-authorship.
ORCID 0000-0002-4946-7926
0000-0002-8662-9656
0000-0002-4308-0405
0000-0002-6602-983X
OpenAccessLink https://doaj.org/article/112de698df5f4edbabc02741987d73e7
PMID 34579259
PQID 2576535967
PQPubID 2032320
ParticipantIDs doaj_primary_oai_doaj_org_article_112de698df5f4edbabc02741987d73e7
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8473382
proquest_miscellaneous_2577447898
proquest_journals_2576535967
crossref_primary_10_3390_vaccines9091022
crossref_citationtrail_10_3390_vaccines9091022
PublicationCentury 2000
PublicationDate 20210914
PublicationDateYYYYMMDD 2021-09-14
PublicationDate_xml – month: 9
  year: 2021
  text: 20210914
  day: 14
PublicationDecade 2020
PublicationPlace Basel
PublicationPlace_xml – name: Basel
PublicationTitle Vaccines (Basel)
PublicationYear 2021
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References ref_12
ref_11
Sandberg (ref_13) 2020; 43
Mahajan (ref_4) 2021; 64
Mahase (ref_15) 2021; 373
Ozonoff (ref_16) 2021; 21
ref_8
Hasan (ref_9) 2021; 14
Groothuis (ref_1) 2016; 53
Rath (ref_2) 2017; 35
Willison (ref_3) 2016; 388
Seabroke (ref_14) 2016; 39
ref_5
ref_7
Waheed (ref_10) 2021; 13
ref_6
References_xml – ident: ref_12
  doi: 10.1001/jamainternmed.2021.2219
– volume: 53
  start-page: 337
  year: 2016
  ident: ref_1
  article-title: Neuralgic amyotrophy: An update on diagnosis, pathophysiology, and treatment
  publication-title: Muscle Nerve
  doi: 10.1002/mus.25008
– volume: 21
  start-page: 450
  year: 2021
  ident: ref_16
  article-title: Bell’s palsy and SARS-CoV-2 vaccines
  publication-title: Lancet Infect. Dis.
  doi: 10.1016/S1473-3099(21)00076-1
– ident: ref_6
  doi: 10.1007/s00415-021-10462-4
– volume: 373
  start-page: n1046
  year: 2021
  ident: ref_15
  article-title: Covid-19: Unusual blood clots are “very rare side effect” of Janssen vaccine, says EMA
  publication-title: BMJ
  doi: 10.1136/bmj.n1046
– ident: ref_5
  doi: 10.1002/pmrj.12619
– volume: 43
  start-page: 999
  year: 2020
  ident: ref_13
  article-title: Risk Factor Considerations in Statistical Signal Detection: Using Subgroup Disproportionality to Uncover Risk Groups for Adverse Drug Reactions in VigiBase
  publication-title: Drug Saf.
  doi: 10.1007/s40264-020-00957-w
– volume: 39
  start-page: 355
  year: 2016
  ident: ref_14
  article-title: Performance of Stratified and Subgrouped Disproportionality Analyses in Spontaneous Databases
  publication-title: Drug Saf.
  doi: 10.1007/s40264-015-0388-3
– volume: 64
  start-page: E3
  year: 2021
  ident: ref_4
  article-title: Parsonage Turner syndrome after COVID-19 vaccination
  publication-title: Muscle Nerve
  doi: 10.1002/mus.27255
– volume: 13
  start-page: e13426
  year: 2021
  ident: ref_10
  article-title: Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 Vaccine
  publication-title: Cureus
– volume: 388
  start-page: 717
  year: 2016
  ident: ref_3
  article-title: Guillain-Barré syndrome
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)00339-1
– volume: 14
  start-page: e243629
  year: 2021
  ident: ref_9
  article-title: Case of Guillain-Barré syndrome following COVID-19 vaccine
  publication-title: BMJ Case Rep.
  doi: 10.1136/bcr-2021-243629
– ident: ref_11
  doi: 10.1002/ana.26144
– ident: ref_7
  doi: 10.1007/s00415-021-10617-3
– ident: ref_8
  doi: 10.1093/qjmed/hcab143
– volume: 35
  start-page: 1972
  year: 2017
  ident: ref_2
  article-title: Facial nerve palsy including Bell’s palsy: Case definitions and guidelines for collection, analysis, and presentation of immunisation safety data
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2016.05.023
SSID ssj0000913867
Score 2.2656214
Snippet Since marketing authorization, cases of neuralgic amyotrophy (NA), facial paralysis/Bell’s palsy (FP/BP), and Guillain-Barré syndrome (GBS) were reported with...
Since marketing authorization, cases of neuralgic amyotrophy (NA), facial paralysis/Bell's palsy (FP/BP), and Guillain-Barré syndrome (GBS) were reported with...
SourceID doaj
pubmedcentral
proquest
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 1022
SubjectTerms acute inflammatory neuropathy
Age
Bell's palsy
Brief Report
Confidence intervals
Coronaviruses
COVID-19
COVID-19 vaccines
Decision making
disproportionality
Guillain-Barre syndrome
Inflammation
Influenza
Males
Neuropathy
Paralysis
Patients
Risk factors
Risk groups
safety
Sex
Subgroups
Vaccines
VigiBase
SummonAdditionalLinks – databaseName: Biological Science Database
  dbid: M7P
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagcOAC5aUGCjISqjg0dOvX2FxQH1RUQmUPZdVb5FfaSCVZNruV-u-xnexugwQXrvFYiTLjefsbhN5TSo210uTElzZnYFxuQIucWArUOia4TZz-Bmdn8uJCjfuEW9u3VS51YlLUrrExR74XHWNOuRLweforj1OjYnW1H6FxHz2IKAk0te6NVzmWiHkpBXSIPjRE93s32sZ6dauimSRkYIwSZv_A0Ry2Sd6xOydP_veLN9Hj3uPEB52IPEX3fP0M7Yw7yOrbXXy-voHV7uIdPF6DWd8-R4vOQw8GDjclPrCLucendRnk6Geqz-OE7pHmGvsWx6wuPvo-OT3O9xWe9L_hEw7qKV0fwcdVO41zGWZdCjKEALiDRQmbqxpPqsvqMNjVF-jHyZfzo695P6oht0yweU6IYjawlgujtBdOE1JKQmNNkIBhbhQkwvF9bcAx8Ny4QAjcjSxwHXQGpS_RRt3UfgthDqqkoIIiBsFG1mugnAlSChhp0KzM0Mclzwrb45jHcRrXRYhnIpOLP5icoQ-rDdMOwuPvpIdRCFZkEXs7PWhml0V_lEPMRJwXSrqSl8w7o41NIEBKggPqIUPbS3koeoXQFmthyNC71XI4yrE-o2vfLBINMAZSyQzBQPQGHzRcqaurBAoevAxKJXn175e_Ro9IbMqJMzDYNtqYzxb-DXpob-ZVO3ubTs9v9hsqKQ
  priority: 102
  providerName: ProQuest
Title Reporting of Acute Inflammatory Neuropathies with COVID-19 Vaccines: Subgroup Disproportionality Analyses in VigiBase
URI https://www.proquest.com/docview/2576535967
https://www.proquest.com/docview/2577447898
https://pubmed.ncbi.nlm.nih.gov/PMC8473382
https://doaj.org/article/112de698df5f4edbabc02741987d73e7
Volume 9
WOSCitedRecordID wos000702070000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2076-393X
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000913867
  issn: 2076-393X
  databaseCode: DOA
  dateStart: 20130101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2076-393X
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000913867
  issn: 2076-393X
  databaseCode: M~E
  dateStart: 20130101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVPQU
  databaseName: Biological Science Database
  customDbUrl:
  eissn: 2076-393X
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000913867
  issn: 2076-393X
  databaseCode: M7P
  dateStart: 20130301
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/biologicalscijournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Proquest Central
  customDbUrl:
  eissn: 2076-393X
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000913867
  issn: 2076-393X
  databaseCode: BENPR
  dateStart: 20130301
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Publicly Available Content Database
  customDbUrl:
  eissn: 2076-393X
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000913867
  issn: 2076-393X
  databaseCode: PIMPY
  dateStart: 20130301
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Research Library (ProQuest)
  customDbUrl:
  eissn: 2076-393X
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000913867
  issn: 2076-393X
  databaseCode: M2O
  dateStart: 20130301
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/pqrl
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELdg8MALGl-ibFRGQhMPC2v9dTFv69aJSqyL0KjKU5TYDkSCdGraSXvhb-fsZF2DhHjhxQ_xWXJ8d747n_07Qt5yznNj4jxirjCRgNxGOWQqYoYDN1YoaQKnP8F0Gs_nOtkq9eXvhDXwwM3CHaE_YJ3SsS1kIZzNs9wEyBWMlS1wF96Ro9ezFUyFPVgPeaygwfLhGNcfXWfGZ6pr7Q0kYx0zFND6Oy5m94LklsU52yWPW1eRHjdTfELuueopOUgarOmbQ3p593SqPqQHNLlDob55RtaNa42WiS4KemzWK0cnVYEC8DMk1mmA5QgFiV1N_XEsPbmYTU6joaaz9i8-UNxXwrsPelrWV76gwrI5O0TfnTZ4Jji4rOis_FaO0CA-J1_OxpcnH6O2xkJkhBKriDEtDPJEqlxnTtmMsSJm3CfzGOTCDpCVVg6zHKwAJ3OLhCDtwIDMUNk5f0F2qkXlXhIqQRccNO6goMTAuAy4FIoVCgYZZKLokfe3S56aFoDc18H4kWIg4nmU_sGjHnm3GXDVYG_8nXTkebgh86DZ4QOKUtqKUvovUeqR_VsJSFtNrlMfkEkutcLuN5tu1EGfWMkqt1gHGhACYh33CHQkpzOhbk9Vfg9o3ugecB6zV__jD_bII-bv3PgSF2Kf7KyWa_eaPDTXq7Je9sl9mMd98mA0niaf-0FhsD1nF76FxLe_xtifTM6Tr78Bh68jwg
linkProvider Directory of Open Access Journals
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLamgQQv3BEdA4wEEw_L1vl2YiSEtpVp1UrpQ6n2FhzbGZFGWpp2qH-K34jtpC1Bgrc98BrbimV_PjcffwehV5TSVOs4jYjNdMQgNVEKSkREU6DaMMF12Oke9Pvx-bkcbKCfy7cwPq1yKRODoDZj7WPk-94w5pRLAe8n3yNfNcrfri5LaFSwOLOLH85lK991O25_XxNy8mF4fBrVVQUizQSbRYRIpt0suEilssIoQrKYUH99RSBlpu0mb_iBSsEwsDw1riNw09bAlYO3D4A6kX_DmREkDqmCg1VMx3NsxgIqBiFKZXv_Sml_P15Kr5YJaSi_UCOgYdg20zJ_03Mnd_-3FbqH7tQWNT6sjsB9tGGLB2hnUFFyL3bxcP3CrNzFO3iwJutePETzygNxChyPM3yo5zOLu0Xmzsm3kH-AA3tJqNtsS-yj1vj406jbiQ4kHtXL_hY78Ruex-BOXk583YlpFWJ1Lg6uaF_c4LzAo_wiP3J2wyP0-VqW5DHaLMaFfYIwB5lRkE7RgGBtbRVQzgTJBLQVKJa10N4SI4muedp9uZDLxPlrHlTJH6BqoTerAZOKouTvXY886FbdPLd4-DCeXiS1qHI-ITFWyNhkPGPWpCrVgeRIxmCAWmih7SX-klrglckafC30ctXsRJW_f1KFHc9DH2AMYhm3EDSg3phQs6XIvwbSc2dFURqTrX___AW6dTr82Et63f7ZU3Sb-AQkX--DbaPN2XRun6Gb-mqWl9Pn4eRi9OW6D8IvlTOGzA
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLamgRAv3BGFAUaCiYeFZr6dGAmhbaWi2lT6MKq9ZY7tjEiQlqYd6l_j12E7aUuQ4G0PvMa2ktifz83H30HoJaU00zrJImJzHTHITJSBEhHRFKg2THAdVvoEhsPk7EyOttDP1V0Yn1a5kolBUJuJ9jHyrjeMOeVSQDdv0iJGvf776ffIV5DyJ62rcho1RI7t8odz36p3g55b61eE9D-cHn2MmgoDkWaCzSNCJNPui7jIpLLCKELyhFB_lEUgYyZ2P2L4vsrAMLA8M64jcBNr4MpB3QdDnfi_Bp60PKQNjtbxHc-3mQio2YQolXH3Uml_Vl5Jr6IJaSnCUC-gZeS2UzR_03n92__zbN1BtxpLGx_UW-Mu2rLlPbQ7qqm6l3v4dHPzrNrDu3i0IfFe3keL2jNxih1PcnygF3OLB2Xu9s-3kJeAA6tJqOdsK-yj2fjo03jQi_YlHjdL8BY7sRyuzeBeUU19PYpZHXp1rg-u6WDc4KLE4-KiOHT2xAP0-Uqm5CHaLielfYQwB5lTkE4BgWCxtgooZ4LkAmIFiuUd9GaFl1Q3_O2-jMjX1PlxHmDpHwDroNfrAdOauuTvXQ89ANfdPOd4eDCZXaSNCHO-IjFWyMTkPGfWZCrTgfxIJmCAWuignRUW00YQVukGiB30Yt3sRJg_l1KlnSxCH2AMEpl0ELRg3_qgdktZfAlk6M66ojQhj__98ufohsN_ejIYHj9BN4nPS_JlQNgO2p7PFvYpuq4v50U1exY2MUbnV70PfgFWTI-J
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Reporting+of+Acute+Inflammatory+Neuropathies+with+COVID-19+Vaccines%3A+Subgroup+Disproportionality+Analyses+in+VigiBase&rft.jtitle=Vaccines+%28Basel%29&rft.au=Noseda%2C+Roberta&rft.au=Ripellino%2C+Paolo&rft.au=Ghidossi%2C+Sara&rft.au=Bertoli%2C+Raffaela&rft.date=2021-09-14&rft.issn=2076-393X&rft.eissn=2076-393X&rft.volume=9&rft.issue=9&rft_id=info:doi/10.3390%2Fvaccines9091022&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2076-393X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2076-393X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2076-393X&client=summon